{
    "2021-09-09": [
        [
            {
                "time": "",
                "original_text": "药企现金流Top20！应收账款占比高，智飞生物凭“新冠疫苗”现金流暴涨1532%",
                "features": {
                    "keywords": [
                        "药企",
                        "现金流",
                        "智飞生物",
                        "新冠疫苗",
                        "暴涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122)2021年中报点评：业绩超预期 新冠疫苗或成新增长极",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "中报",
                        "业绩",
                        "新冠疫苗",
                        "新增长极"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "疫苗板块2021H1总结：新冠疫苗商业化价值初现 在研管线亮点颇多",
                "features": {
                    "keywords": [
                        "疫苗板块",
                        "新冠疫苗",
                        "商业化价值",
                        "在研管线"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}